NO20033241L - Fremgangsmåte - Google Patents

Fremgangsmåte

Info

Publication number
NO20033241L
NO20033241L NO20033241A NO20033241A NO20033241L NO 20033241 L NO20033241 L NO 20033241L NO 20033241 A NO20033241 A NO 20033241A NO 20033241 A NO20033241 A NO 20033241A NO 20033241 L NO20033241 L NO 20033241L
Authority
NO
Norway
Prior art keywords
liquid
particles
substance
temperature
modulator
Prior art date
Application number
NO20033241A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033241D0 (no
Inventor
Goeran Eric Sundholm
Mustafa Demirbueker
Saeed Moshashaee
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20033241D0 publication Critical patent/NO20033241D0/no
Publication of NO20033241L publication Critical patent/NO20033241L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D11/00Solvent extraction
    • B01D11/04Solvent extraction of solutions which are liquid
    • B01D11/0403Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20033241A 2001-01-26 2003-07-17 Fremgangsmåte NO20033241L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0102075.9A GB0102075D0 (en) 2001-01-26 2001-01-26 Process
PCT/GB2002/000261 WO2002058674A2 (en) 2001-01-26 2002-01-22 Process for preparing particles

Publications (2)

Publication Number Publication Date
NO20033241D0 NO20033241D0 (no) 2003-07-17
NO20033241L true NO20033241L (no) 2003-07-17

Family

ID=9907591

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033241A NO20033241L (no) 2001-01-26 2003-07-17 Fremgangsmåte

Country Status (21)

Country Link
US (2) US7108867B2 (da)
EP (1) EP1357901B1 (da)
JP (1) JP4175892B2 (da)
KR (1) KR100853596B1 (da)
CN (1) CN1298312C (da)
AT (1) ATE354352T1 (da)
BR (1) BR0206439A (da)
CA (1) CA2433838A1 (da)
CY (1) CY1106550T1 (da)
DE (1) DE60218285T2 (da)
DK (1) DK1357901T3 (da)
ES (1) ES2281509T3 (da)
GB (1) GB0102075D0 (da)
IL (2) IL156720A0 (da)
MX (1) MXPA03006537A (da)
NO (1) NO20033241L (da)
NZ (1) NZ526942A (da)
PT (1) PT1357901E (da)
SI (1) SI1357901T1 (da)
WO (1) WO2002058674A2 (da)
ZA (1) ZA200304953B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP2006516958A (ja) * 2002-12-19 2006-07-13 バクスター・インターナショナル・インコーポレイテッド 超臨界流体を用いた組み合わせ薬学的処方物を調製するためのプロセス
JP5207432B2 (ja) * 2003-04-29 2013-06-12 エム・エス・ディー・オス・ベー・フェー アンチ溶媒凝固プロセス
WO2004098561A2 (en) 2003-05-08 2004-11-18 Nektar Therapeutics Uk Ltd Particulate materials
US20050181059A1 (en) * 2003-09-30 2005-08-18 Spherics, Inc. Nanoparticulate therapeutic biologically active agents
US7220456B2 (en) 2004-03-31 2007-05-22 Eastman Kodak Company Process for the selective deposition of particulate material
US7223445B2 (en) 2004-03-31 2007-05-29 Eastman Kodak Company Process for the deposition of uniform layer of particulate material
EP1904219A4 (en) * 2005-07-15 2011-07-27 Map Pharmaceuticals Inc METHOD FOR FORMING PARTICLES
NL1031224C2 (nl) * 2006-02-23 2007-09-03 Friesland Brands Bv Het bereiden van gedroogde deeltjes met behulp van een superkritisch medium.
US20080187568A1 (en) * 2007-02-06 2008-08-07 Sawhney Amarpreet S Polymerization with precipitation of proteins for elution in physiological solution
DK2425820T3 (da) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc Fremgangsmåde til terapeutisk administration af dhe for at muliggøre hurtig lindring af migræne, mens bivirkningsprofilen minimeres
JP5307382B2 (ja) * 2007-11-14 2013-10-02 日機装株式会社 微粒子化方法
PL2229233T3 (pl) * 2007-12-07 2020-03-31 Xspray Pharma Ab (Publ) Sposób wytwarzania cząstek
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
EP4324475A1 (en) * 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP6668652B2 (ja) 2015-09-18 2020-03-18 日本精工株式会社 直動案内装置、直動案内装置用エンドキャップ
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
AU2022304547B2 (en) * 2021-06-28 2025-03-06 Micro Motion, Inc. Coriolis flow meter non-ideal fluid measurement and related methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0432232T3 (da) 1989-05-01 1994-01-31 Alkermes Inc Fremgangsmåde til fremstilling af små partikler af biologisk aktive molekyler
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
CA2234957C (en) 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB9804379D0 (en) 1998-03-02 1998-04-22 Bradford Particle Design Ltd Method of particle formation
CA2326349A1 (en) * 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
SE9801287D0 (sv) 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
GB9810559D0 (en) 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
SE9804001D0 (sv) 1998-11-23 1998-11-23 Astra Ab New process
GB9828204D0 (en) 1998-12-21 1999-02-17 Smithkline Beecham Plc Process
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
GB9920558D0 (en) 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
EP1425355A1 (en) * 2001-07-12 2004-06-09 Eastman Kodak Company A compressed fluid formulation
US6998051B2 (en) * 2002-07-03 2006-02-14 Ferro Corporation Particles from supercritical fluid extraction of emulsion
EP1727520A2 (en) * 2003-12-09 2006-12-06 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing

Also Published As

Publication number Publication date
MXPA03006537A (es) 2003-09-22
DK1357901T3 (da) 2007-06-04
NO20033241D0 (no) 2003-07-17
KR100853596B1 (ko) 2008-08-22
US20070009604A1 (en) 2007-01-11
CY1106550T1 (el) 2012-01-25
CN1487825A (zh) 2004-04-07
GB0102075D0 (en) 2001-03-14
CA2433838A1 (en) 2002-08-01
WO2002058674A2 (en) 2002-08-01
DE60218285T2 (de) 2007-11-15
DE60218285D1 (de) 2007-04-05
US7108867B2 (en) 2006-09-19
PT1357901E (pt) 2007-05-31
BR0206439A (pt) 2003-12-30
AU2002225193B2 (en) 2006-07-27
NZ526942A (en) 2005-04-29
KR20030070921A (ko) 2003-09-02
JP4175892B2 (ja) 2008-11-05
EP1357901B1 (en) 2007-02-21
IL156720A0 (en) 2004-01-04
ZA200304953B (en) 2004-08-25
SI1357901T1 (sl) 2007-08-31
HK1063157A1 (en) 2004-12-17
US20040058007A1 (en) 2004-03-25
JP2004521891A (ja) 2004-07-22
US7829123B2 (en) 2010-11-09
IL156720A (en) 2010-03-28
ES2281509T3 (es) 2007-10-01
CN1298312C (zh) 2007-02-07
EP1357901A2 (en) 2003-11-05
ATE354352T1 (de) 2007-03-15
WO2002058674A3 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
NO20033241D0 (no) Fremgangsmåte
DK1528953T3 (da) Fremgangsmåde og anordning til stripning af ammoniak fra væsker
NO20071094L (no) Fremgangsmate og anordning for overforing av varme fra en varmekilde til en termodynamisk krets med et arbeidsmiddel med minst to stoff med ikke-isaterm fordampning og kondensering
NO20071432L (no) Fremgangsmate for konsentrasjon av antistoffer of terapeutiske produkter derav.
MY139229A (en) Method of removing organic impurities from water
MY138913A (en) Removing contaminants from natural gas
KR960701083A (ko) 단백질 재생을 위한 개선된 방법(improved method for the refolding of proteins)
NO20081986L (no) Oljebasert isolerende pakningsfluid
NO20080658L (no) Fremgangsmate for a gjenvinne en polymer fra et flytende medium
ATE377044T1 (de) Gel auf der basis von polysacchariden
DE60236529D1 (de) Verfahren zur herstellung von polyarylensulfid
YU49434B (sh) Postupak za proizvodnju tečnosti bogate metanom
DK63988D0 (da) Fremgangsmaade til forflydning af roer og cikorieroedder ved enzymatisk hydrolyse samt det derved fremkomne flydende hydrolysat
ATE551991T1 (de) Formulierung aus feinen teilchen mit verflüssigten oder dichten gasen
DK1407052T3 (da) Fremgangsmåde til overvågning og modulering af proteinfoldning
ATE329900T1 (de) Verfahren zur herstellung von 2-pyrrolidon
BR112022012982A2 (pt) Nanofluido para redução da migração de finos e recuperação de petróleo aprimorado, método de preparação e usos
Qi et al. Novel isoelectric precipitation of proteins in a pressurized carbon dioxide‐water‐ethanol system
MX167405B (es) Procedimiento para la produccion de poliaminas
TW200641101A (en) Etching solution for liquid crystal polymer and method for etching liquid crystal polymer
BR9915484A (pt) Processo para o isolamento contìnuo de proteìnas ativas
CN116478963A (zh) 一种耐热α-L-鼠李糖苷酶及其制备方法和应用
NO20064455L (no) Vaeskeprovetakingsapparat og fremgangsmate ved bruk av samme
Primozic et al. Proteinase-catalyzed hydrolysis of casein at atmospheric pressure and in supercritical media
Campaigne et al. Some Derivatives of o-Hydroxy-and o-Mercaptothioanisole.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application